Skip to content

FD 102 - Palopegteriparatida aprovado pela ANVISA para hipoparatireoidismo

September 25, 2026 · 11 min

Show notes

Neste FD vamos discutir sobre a recente aprovãção da ANVISA da medicação palopegteriparatida no tratamento de pacientes com hipoparatireoidismo crônico.

Acesse: endodirect.com.br

Referencias

Khan AA et al. JBMR 2023;

Clarke BL et al. JCEM 2025;

Rejnmark L et al. JBMR 2026;

Khan AA et al. JCEM 2022

Khan AA et al. JBMR 2022

All episodes of EndoDirect – Endocrinologia e Metabologia

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.